CA3066048A1 - Polytherapie - Google Patents

Polytherapie Download PDF

Info

Publication number
CA3066048A1
CA3066048A1 CA3066048A CA3066048A CA3066048A1 CA 3066048 A1 CA3066048 A1 CA 3066048A1 CA 3066048 A CA3066048 A CA 3066048A CA 3066048 A CA3066048 A CA 3066048A CA 3066048 A1 CA3066048 A1 CA 3066048A1
Authority
CA
Canada
Prior art keywords
antibody
icos
antigen binding
binding portion
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3066048A
Other languages
English (en)
Inventor
Meixia BI
Christopher B. Hopson
Patrick A. MAYES
Sapna YADAVILLI
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of CA3066048A1 publication Critical patent/CA3066048A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne des procédés de traitement du cancer chez un patient en ayant besoin, le procédé comprenant l'administration au patient d'une quantité efficace d'un agent dirigé contre l'ICOS humain et d'une quantité efficace d'un agent dirigé contre PD-1 humain ou PD-Ll humain séquentiellement. L'invention concerne également un anticorps anti-ICOS ou un fragment de liaison à l'antigène de celui-ci et un anticorps anti-PD-1 ou un fragment de liaison à l'antigène de celui-ci pour une utilisation séquentielle dans le traitement du cancer chez un être humain qui en a besoin. L'invention concerne un anticorps anti-ICOS ou un fragment de liaison à l'antigène de celui-ci et un anticorps anti-PD-Ll ou un fragment de liaison à l'antigène de celui-ci pour une utilisation séquentielle dans le traitement du cancer chez un être humain qui en a besoin.
CA3066048A 2017-06-09 2018-06-08 Polytherapie Pending CA3066048A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762517309P 2017-06-09 2017-06-09
US62/517,309 2017-06-09
US201862666278P 2018-05-03 2018-05-03
US62/666,278 2018-05-03
PCT/IB2018/054167 WO2018225033A1 (fr) 2017-06-09 2018-06-08 Polythérapie

Publications (1)

Publication Number Publication Date
CA3066048A1 true CA3066048A1 (fr) 2018-12-13

Family

ID=62873504

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3066048A Pending CA3066048A1 (fr) 2017-06-09 2018-06-08 Polytherapie

Country Status (6)

Country Link
EP (1) EP3634483A1 (fr)
JP (1) JP2020522555A (fr)
CN (1) CN110869049A (fr)
BR (1) BR112019025325A2 (fr)
CA (1) CA3066048A1 (fr)
WO (1) WO2018225033A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20260030924A (ko) 2016-08-09 2026-03-06 키맵 리미티드 항-icos 항체
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (fr) 2017-12-19 2020-10-28 Kymab Limited Anticorps bispécifique pour icos et pd-l1
AU2021256652A1 (en) * 2020-04-14 2022-11-03 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer involving anti-ICOS and anti-PD1 antibodies, optionally further involving anti-tim3 antibodies
AU2021256925A1 (en) * 2020-04-14 2022-11-03 Ares Trading S.A. Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
WO2003042402A2 (fr) 2001-11-13 2003-05-22 Dana-Farber Cancer Institute, Inc. Agents modulant l'activite de cellules immunes et procedes d'utilisation associes
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
CN1753912B (zh) 2002-12-23 2011-11-02 惠氏公司 抗pd-1抗体及其用途
US7563869B2 (en) 2003-01-23 2009-07-21 Ono Pharmaceutical Co., Ltd. Substance specific to human PD-1
RU2494107C2 (ru) 2005-05-09 2013-09-27 Оно Фармасьютикал Ко., Лтд. Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
EP2068925A4 (fr) 2007-05-07 2011-08-31 Medimmune Llc Anticorps anti-icos et leur utilisation en traitement oncologique, de transplantation et maladie auto-immune
HRP20131167T1 (hr) 2007-06-18 2014-01-03 Merck Sharp & Dohme B.V. Antitijela za humani receptor programirane smrti pd-1
WO2009114335A2 (fr) 2008-03-12 2009-09-17 Merck & Co., Inc. Protéines de liaison avec pd-1
WO2010098788A2 (fr) 2008-08-25 2010-09-02 Amplimmune, Inc. Antagonistes de pd-i et procédés de traitement d'une maladie infectieuse
JP5794917B2 (ja) 2008-09-12 2015-10-14 アイシス・イノベーション・リミテッドＩｓｉｓ Ｉｎｎｏｖａｔｉｏｎｌｉｍｉｔｅｄ Ｐｄ−１特異抗体およびその使用
US8927697B2 (en) 2008-09-12 2015-01-06 Isis Innovation Limited PD-1 specific antibodies and uses thereof
KR101814408B1 (ko) 2008-09-26 2018-01-04 다나-파버 캔서 인스티튜트 인크. 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
EP3375791A1 (fr) * 2009-09-30 2018-09-19 Memorial Sloan Kettering Cancer Center Immunothérapie combinée pour le traitement du cancer
WO2011066342A2 (fr) 2009-11-24 2011-06-03 Amplimmune, Inc. Inhibition simultanée de pd-l1/pd-l2
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
CN101898945B (zh) 2010-07-27 2013-05-08 大连理工大学 盐析萃取发酵液中丙酮和丁醇的方法
ES2612914T3 (es) 2011-03-31 2017-05-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra Icos y usos de los mismos
JP6238459B2 (ja) 2011-08-01 2017-11-29 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
EP2744830A4 (fr) * 2012-06-21 2015-06-17 Compugen Ltd Anticorps anti-lsr et leurs utilisations pour le traitement du cancer
EP2892928B1 (fr) 2012-09-03 2018-05-30 INSERM - Institut National de la Santé et de la Recherche Médicale Anticorps anti-icos pour traiter la maladie du greffon contre l'hôte
CA2886433C (fr) 2012-10-04 2022-01-04 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux humains anti pd-l1 et procedes d'utilisation
CA2920377A1 (fr) * 2013-08-05 2015-02-12 Cambridge Enterprise Limited Inhibition de la signalisation cxr4 en immunotherapie anticancereuse
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
TWI719970B (zh) 2015-03-23 2021-03-01 美商永斯醫療股份有限公司 針對ｉｃｏｓ之抗體
EP3331919A1 (fr) * 2015-08-07 2018-06-13 GlaxoSmithKline Intellectual Property Development Limited Polythérapie comprenant des anticorps anti-ctla-4

Also Published As

Publication number Publication date
WO2018225033A1 (fr) 2018-12-13
EP3634483A1 (fr) 2020-04-15
CN110869049A (zh) 2020-03-06
BR112019025325A2 (pt) 2020-06-23
JP2020522555A (ja) 2020-07-30

Similar Documents

Publication Publication Date Title
JP2022065073A (ja) Ｂｃｍａ結合分子及びその使用方法
JP7325959B2 (ja) 腫瘍特異的細胞の枯渇のための抗ＣＤ２５ ＦＣγ受容体二重特異性抗体
JP7581225B2 (ja) Ｃｔｌａ－４遮断剤とｐｄ－１遮断剤とを含む抗癌併用療法
KR20190039421A (ko) 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
JP7383620B2 (ja) 養子細胞療法およびチェックポイント阻害剤を使用する併用療法
CA3066048A1 (fr) Polytherapie
WO2018025221A1 (fr) Polythérapie à base d'anticorps anti-icos et anti-pd-1
CN115135344A (zh) 在疗法中使用的抗体
KR20200140315A (ko) 항-cd27 항체 및 그의 용도
KR20220025739A (ko) T-세포 활성화를 위한 항체
WO2023285552A1 (fr) Agents de liaison multispécifiques contre cd40 et cd137 en polythérapie du cancer
WO2024022324A9 (fr) Cellules immunitaires modifiées
US20200181275A1 (en) Combination therapy with icos agonist and ox40 agonist to treat cancer
US20200190194A1 (en) Combination therapy
WO2020086476A1 (fr) Schéma posologique
US20200190195A1 (en) Combination therapy with icos agonist and ox40 agonist to treat cancer
HK40110611A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
WO2024209072A1 (fr) Agents de liaison multispécifiques dirigés contre pd-l1 et cd137 pour le traitement du cancer
CN117957253A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
HK40081753A (en) Antibodies for use in therapy
EA040773B1 (ru) Анти-tigit антитела, анти-pvrig антитела и их комбинации